S1PR1 and autoimmune disease: As they demonstrated in vivo efficacy in the EAE model, and due to their S1P1-selective nature, we speculate that they will exhibit fewer adverse effects and have an advantage over fingolimod and siponimod, not only in MS but also in other autoimmune diseases.